This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.
We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.
Tony Bourne has considerable experience and knowledge of the healthcare and financial services industries. He was Chief Executive of the British Medical Association between 2005 and 2013. Prior to this he was in investment banking for over 25 years, including as a partner of independent corporate finance advisory firm Hawkpoint, as global head of the equities division and a member of the managing board of Paribas and held senior roles at Merrill Lynch, European Banking Company and James Capel & Co.
Tony currently serves as Chair of CW+ (the official charity of Chelsea and Westminster Hospital NHS Foundation Trust), and is additionally an Independent Non-Executive Director to the Boards of Barchester Healthcare, Spire Healthcare Group PLC and Totally PLC.
Sir Bruce Keogh, Non-Executive Chairman of Sensyne, said
“I’m delighted to welcome Tony to the Board at a time of tremendous progress for Sensyne. His track record and deep expertise in the healthcare space, as well as a distinguished career in the financial services industry, will be invaluable to us as we embark on the next phase of our growth – building an innovative world class clinical data and artificial intelligence company.”
The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
Full name and age: Anthony (Tony) Rhys Bourne (age 67)
Current Directorships or Partnerships:
Directorships or Partnerships within the last five years
No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.
Tony Bourne has considerable experience and knowledge of the healthcare and financial services industries. He was Chief Executive of the British Medical Association between 2005 and 2013. Prior to this he was in investment banking for over 25 years, including as a partner of independent corporate finance advisory firm Hawkpoint, as global head of the equities division and a member of the managing board of Paribas and held senior roles at Merrill Lynch, European Banking Company and James Capel & Co.
Tony currently serves as Chair of CW+ (the official charity of Chelsea and Westminster Hospital NHS Foundation Trust), and is additionally an Independent Non-Executive Director to the Boards of Barchester Healthcare, Spire Healthcare Group PLC and Totally PLC.
Sir Bruce Keogh, Non-Executive Chairman of Sensyne, said
“I’m delighted to welcome Tony to the Board at a time of tremendous progress for Sensyne. His track record and deep expertise in the healthcare space, as well as a distinguished career in the financial services industry, will be invaluable to us as we embark on the next phase of our growth – building an innovative world class clinical data and artificial intelligence company.”
The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
Full name and age: Anthony (Tony) Rhys Bourne (age 67)
Current Directorships or Partnerships:
Directorships or Partnerships within the last five years
No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.
Tony Bourne has considerable experience and knowledge of the healthcare and financial services industries. He was Chief Executive of the British Medical Association between 2005 and 2013. Prior to this he was in investment banking for over 25 years, including as a partner of independent corporate finance advisory firm Hawkpoint, as global head of the equities division and a member of the managing board of Paribas and held senior roles at Merrill Lynch, European Banking Company and James Capel & Co.
Tony currently serves as Chair of CW+ (the official charity of Chelsea and Westminster Hospital NHS Foundation Trust), and is additionally an Independent Non-Executive Director to the Boards of Barchester Healthcare, Spire Healthcare Group PLC and Totally PLC.
Sir Bruce Keogh, Non-Executive Chairman of Sensyne, said
“I’m delighted to welcome Tony to the Board at a time of tremendous progress for Sensyne. His track record and deep expertise in the healthcare space, as well as a distinguished career in the financial services industry, will be invaluable to us as we embark on the next phase of our growth – building an innovative world class clinical data and artificial intelligence company.”
The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
Full name and age: Anthony (Tony) Rhys Bourne (age 67)
Current Directorships or Partnerships:
Directorships or Partnerships within the last five years
No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.
Tony Bourne has considerable experience and knowledge of the healthcare and financial services industries. He was Chief Executive of the British Medical Association between 2005 and 2013. Prior to this he was in investment banking for over 25 years, including as a partner of independent corporate finance advisory firm Hawkpoint, as global head of the equities division and a member of the managing board of Paribas and held senior roles at Merrill Lynch, European Banking Company and James Capel & Co.
Tony currently serves as Chair of CW+ (the official charity of Chelsea and Westminster Hospital NHS Foundation Trust), and is additionally an Independent Non-Executive Director to the Boards of Barchester Healthcare, Spire Healthcare Group PLC and Totally PLC.
Sir Bruce Keogh, Non-Executive Chairman of Sensyne, said
“I’m delighted to welcome Tony to the Board at a time of tremendous progress for Sensyne. His track record and deep expertise in the healthcare space, as well as a distinguished career in the financial services industry, will be invaluable to us as we embark on the next phase of our growth – building an innovative world class clinical data and artificial intelligence company.”
The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
Full name and age: Anthony (Tony) Rhys Bourne (age 67)
Current Directorships or Partnerships:
Directorships or Partnerships within the last five years
No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.
Tony Bourne has considerable experience and knowledge of the healthcare and financial services industries. He was Chief Executive of the British Medical Association between 2005 and 2013. Prior to this he was in investment banking for over 25 years, including as a partner of independent corporate finance advisory firm Hawkpoint, as global head of the equities division and a member of the managing board of Paribas and held senior roles at Merrill Lynch, European Banking Company and James Capel & Co.
Tony currently serves as Chair of CW+ (the official charity of Chelsea and Westminster Hospital NHS Foundation Trust), and is additionally an Independent Non-Executive Director to the Boards of Barchester Healthcare, Spire Healthcare Group PLC and Totally PLC.
Sir Bruce Keogh, Non-Executive Chairman of Sensyne, said
“I’m delighted to welcome Tony to the Board at a time of tremendous progress for Sensyne. His track record and deep expertise in the healthcare space, as well as a distinguished career in the financial services industry, will be invaluable to us as we embark on the next phase of our growth – building an innovative world class clinical data and artificial intelligence company.”
The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
Full name and age: Anthony (Tony) Rhys Bourne (age 67)
Current Directorships or Partnerships:
Directorships or Partnerships within the last five years
No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.
